Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis

BACKGROUND: Chemoresistance is the main reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and compounds to reverse chemotherapeutic resistance. METHODS: We established a bio-bank of human PDAC organoid models, covering a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Tianxing, Xie, Yongjie, Hou, Xupeng, Bai, Weiwei, Li, Xueyang, Liu, Ziyun, Man, Quan, Sun, Jingyan, Fu, Danqi, Yan, Jingrui, Zhang, Zhaoyu, Wang, Yifei, Wang, Hongwei, Jiang, Wenna, Gao, Song, Zhao, Tiansuo, Chang, Antao, Wang, Xiuchao, Sun, Hongxia, Zhang, Xiufeng, Yang, Shengyu, Huang, Chongbiao, Hao, Jihui, Liu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157938/
https://www.ncbi.nlm.nih.gov/pubmed/37143164
http://dx.doi.org/10.1186/s13046-023-02671-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157938/
https://www.ncbi.nlm.nih.gov/pubmed/37143164
http://dx.doi.org/10.1186/s13046-023-02671-8

Ejemplares similares